Parkinson’s disease research shifts toward proteoform-level resolution with Nautilus Biotechnology’s platform
Find out how proteoform-level proteomics could transform Parkinson’s biomarker research and reshape future clinical trials.
Pharma & Biotech
Pharma & Biotech
How Insilico Medicine’s ISM8969 could unlock a new class of neuroinflammatory drugs
Insilico’s AI-designed drug ISM8969 enters Phase 1 for Parkinson’s disease. Find out what this NLRP3 candidate could mean for CNS drug development.
Pharma & Biotech
Insilico, Hygtia Therapeutics to co-develop brain-penetrant NLRP3 inhibitor ISM8969 for CNS diseases
Clinical-stage biotechnology company Insilico Medicine (HKEX: 3696) and Hygtia Therapeutics, a Shenzhen Pengfu Fund–backed startup under Fosun Health Capital, have entered into an exclusive co-development and licensing agreement to jointly advance ISM8969, a novel brain-penetrant NLRP3 inhibitor for central nervous system diseases. The deal grants 50-50 worldwide rights to both companies, with Insilico eligible to
Pharma & Biotech
iRegene’s NouvNeu001 becomes first iPSC therapy with RMAT and Fast Track designations
Find out how iRegene’s iPSC-based Parkinson’s therapy NouvNeu001 became the first to earn both RMAT and Fast Track status from the FDA.
Pharma & Biotech
Can Amneal’s Parkinson’s strategy evolve beyond symptoms? KeifeRx tie-up may signal shift
KeifeRx and Amneal join forces on KFRX06, a brain-penetrant LRRK2 inhibitor for Parkinson’s. Find out what this could mean for CNS innovation.
Pharma & Biotech
Ventyx to give Lilly an oral inflammation pipeline—what’s the real upside?
Eli Lilly and Company has announced plans to acquire Ventyx Biosciences Inc. in an all-cash transaction valued at approximately $1.2 billion, securing a portfolio of clinical-stage oral small molecule therapeutics focused on chronic inflammatory-mediated diseases. The deal includes NLRP3 inhibitors such as VTX2735 and VTX3232, alongside two Phase 2 programs for inflammatory bowel disease. The
Pharma & Biotech
From Parkinson’s to platform scalability: What’s next for Sinopia’s LEADS technology
Sinopia Biosciences receives NIH grant to expand its LEADS platform. Find out how AI and metabolomics could transform drug discovery.
Pharma & Biotech
Meta-Flux and Mercury Bio team up to target intracellular CNS pathways with precision
Mercury Bio Inc., a biotechnology company focused on large-molecule therapeutics, has announced a strategic collaboration with Meta-Flux, a disease simulation company that leverages artificial intelligence, to advance drug discovery programs for Parkinson’s disease and Alzheimer’s disease. The partnership combines Mercury Bio’s proprietary yeast extracellular vesicle (yEV) delivery technology with Meta-Flux’s disease-scale computational modeling platform, with
Medical Devices & Diagnostics
What the nanoparticle BCI model reveals about the future of brain interfaces
Subsense, Inc. has raised an additional $10 million in funding to accelerate the development of its non-surgical, nanoparticle-based brain-computer interface (BCI), bringing its total funding to $27 million. The financing, led by Golden Falcon Capital, follows early successes in nanoparticle design, in vitro signal stimulation, and the construction of a bio-integrated hardware-software platform intended to
Pharma & Biotech
How Staccato technology positions Lee’s Pharmaceutical for CNS drug delivery leadership
Lee’s Pharmaceutical Holdings Limited has acquired the Staccato One Breath Technology platform and related assets from Alexza Pharmaceuticals, gaining exclusive rights to manufacture and license Staccato alprazolam under its global agreement with UCB. The transaction expands Lee’s Pharmaceutical’s inhalation drug delivery pipeline, deepens its foothold in central nervous system therapies, and positions the company to